New AI test identifies prostate cancer patients who benefit from abiraterone
A new artificial intelligence (AI) test can identify which men with prostate cancer will benefit most from the life-extending drug abiraterone, in clinical trial results presented by scientists from UCL and the Institute of Cancer Research. The researchers analyzed prostate cancer tumour samples from men with high-risk prostate cancer that had not spread, who took … Read more